The information in news releases is current at the time of the release. Note that the information shown here may not be latest information (termination of production or sales, changes to specifications or pricing, organizational or contact address changes, etc.), and may be subject to change without prior notice.
Letter of Intent Signed on Domestic Marketing and Joint Development of Quinolone Antibiotic T-3811
|January 26, 2006|
Japan, January 26, 2006 - Toyama Chemical Co., Ltd. (“Toyama”; headquarters: Tokyo; president: Katsuhiko Nakano) and Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Toichi Takenaka) today announced that they have signed a letter of intent for the marketing and joint development in Japan of oral formulations of the new-type quinolone antibiotic T-3811 (generic name: garenoxacin) discovered by Toyama. The two companies will sign a definitive license agreement by March 31, 2006.
Profile of T-3811
Development status of T-3811